No announcement yet.

Effect of omega-3 supplementation on EDSS and Inflammatory Cytokines in MS

  • Filter
  • Time
  • Show
Clear All
new posts

  • Effect of omega-3 supplementation on EDSS and Inflammatory Cytokines in MS

    Effect of omega-3 supplementation on Expanded Disability Status Scale and Inflammatory Cytokines in multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials.


    Sedighian M, et al
    CNS & Neurological Disorders Drug Targets [15 May 2019]
    Type: Journal Article
    DOI: 10.2174/1871527318666190516083008


    Recent trial studies have shown that omega-3 supplementation can beneficially improve Expanded Disability Status Scale (EDSS) which considered as a gold standard for measuring disability and disease severity in multiple sclerosis (MS) patients as well as reducing neuroinflammation. The present systematic review and meta-analysis aimed to evaluate the effect of omega-3 supplementation on EDSS and cytokines in MS.

    We performed a systematically search on Pubmed, Scopus and Cochrane Library up to October 2018. Studies were reviewed based on Cochrane handbook and preferred reporting items for systematic reviews and meta-analyses (PRISMA).

    Weighted mean difference (WMD) with 95% confidence intervals (CI) were pooled using random effects model in order to compare the effects of omega-3 with placebo. Among 4 trials, omega3 supplementation had no significant effect on EDSS scale (WMD: -0.07; 95% CI: -0.27 to 0.13; P=0.50) as well as serum levels of IL-1β (WMD: -7.67; 95% CI: -23.31 to 7.97; P=0.34) and IL-6 (WMD: -153.57; 95% CI: -455.36 to 148.23; P=0.32) but omega-3 significantly reduce TNF-α concentration (WMD: -16.76; 95% CI: -18.63 to -14.88; P < 0.00001) compared to placebo.

    Overall, omega-3 supplementation may not have clinically considerable impact on EDSS or proinflammatory markers. However the trials are limit in this context and further clinical trials are required to confirm the potential effect of omega-3 supplement on MS disease management.
    Dave Bexfield